



Diana Crivellari

Kontakt

Diana Crivellari

Publikationen (8)

Pagani O, Winer E, Rabaglio-Poretti M, Maibach R, Ruepp B, Giobbie-Hurder A, Price K, Bernhard J, Luo W, Ribi K, Viale G, Coates A, Gelber R, Goldhirsch A, Francis P, TEXT and SOFT Investigators, Ruhstaller T, Crivellari D, Puglisi F, Regan M, Walley B, Fleming G, Colleoni M, Láng I, Gomez H, Tondini C, Burstein H, Perez E, Ciruelos E, Stearns V, Bonnefoi H, Martino S, Geyer C, Pinotti G, International Breast Cancer Study Group. Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. *N Engl J Med* 2014; 371:107-18.

Paridaens R, Coates A, Crivellari D, Holmberg S, Price K, Thürlimann B, Gelber R, Cole B, Gelber S, Goldhirsch A. Adjuvant! Online estimation of chemotherapy effectiveness when added to ovarian function suppression plus tamoxifen for premenopausal women with estrogen-receptor-positive breast cancer. *Breast Cancer Res Treat* 2010; 123:303-10.

Pagani O, Goldhirsch A, Coates A, Forbes J, Murray E, Fey M, Thürlimann B, Lindtner J, Collins J, Crivellari D, Holmberg S, Gelber R, Price K, Castiglione-Gertsch M, Simoncini E, Gelber S, International Breast Cancer Study Group. Is adjuvant chemotherapy of benefit for postmenopausal women who receive endocrine treatment for highly endocrine-responsive, node-positive breast cancer? International Breast Cancer Study Group Trials VII and 12-93. *Breast Cancer Res Treat* 2009; 116:491-500.

Thürlimann B, Coates A, Castiglione-Gertsch M, Forbes J, Collins J, Colleoni M, Crivellari D, Holmberg S, Gelber R, Price K, Goldhirsch A. Is chemotherapy necessary for premenopausal women with lower-risk node-positive, endocrine responsive breast cancer? 10-year update of International Breast Cancer Study Group Trial 11-93. *Breast Cancer Res Treat* 2009; 113:137-44.

Crivellari D, Chirgwin J, Smith I, Rabaglio M, Gladieff L, Del Mastro L, Láng I, Colleoni M, Gelber R, Castiglione-Gertsch M, Paridaens R, Forbes J, Mauriac L, Mouridsen H, Thürlimann B, Price K, Coates A, Sun Z, Goldhirsch A. Letrozole compared with tamoxifen for elderly patients with endocrine-responsive early breast cancer: the BIG 1-98 trial. *JCO* 2008; 26:1972-9.

Karlsson P, Goldhirsch A, Gelber R, Forbes J, Crivellari D, Thürlimann B, Fey M, Holmberg S, Collins J, Lindtner J, Murray E, Gusterson B, Castiglione-Gertsch M, Coates A, Price K, Cole B, Wallgren A. The role of the number of uninvolved lymph nodes in predicting locoregional recurrence in breast cancer. *JCO* 2007; 25:2019-26.

Gruber G, Goldhirsch A, Coates A, Gelber R, Fey M, Simoncini E, Thürlimann B, Carbone A, Crivellari D, Collins J, Golouh R, Lindtner J, Holmberg S, Rudenstam C, Castiglione-Gertsch M, Price K, Nasi M, Bonetti M, International Breast Cancer Study Group. Prognostic value of extracapsular tumor spread for locoregional control in premenopausal patients with node-positive breast cancer treated with classical cyclophosphamide, methotrexate, and fluorouracil: long-term observations from International Breast Cancer Study Group Trial VI. *JCO* 2005; 23:7089-97.

Colleoni M, Thürlimann B, Crivellari D, Murray E, Mendiola C, Pagani O, Castiglione-Gertsch M, Coates A, Price K, Fey M, Collins J, Zahrieh D, Gelber R, Holmberg S, Mattsson J, Rudenstam C, Lindtner J, Erzen D, Snyder R, Goldhirsch A. Site of primary tumor has a prognostic role in operable breast cancer: the international breast cancer study group experience. *JCO* 2005; 23:1390-400.

Projekte (0)

Keine Resultate gefunden.

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

support.forschung@kssg.ch